These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27121944)

  • 1. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
    Azuma J; Fukase H
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects.
    Shadle CR; Murphy MG; Liu Y; Ho M; Tatosian D; Li SX; Blum RA
    Clin Pharmacol Drug Dev; 2012 Jul; 1(3):93-101. PubMed ID: 27121336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
    Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
    Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
    Olver IN
    Ther Clin Risk Manag; 2008 Apr; 4(2):501-6. PubMed ID: 18728837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
    Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
    Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
    Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
    Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives.
    Candelario N; Lu ML
    Cancer Manag Res; 2016; 8():77-82. PubMed ID: 27382332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
    Kaste M; Murayama S; Ford GA; Dippel DW; Walters MR; Tatlisumak T;
    Cerebrovasc Dis; 2013; 36(3):196-204. PubMed ID: 24135530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
    Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
    Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.